The Medicine Shoppe Pharmacy

medicineshoppe.ca

Programs / Services Specialized Programs and Services for Unique Health Needs At The Medicine Shoppe® pharmacy, we’re committed to providing a higher level of customer care. We continuously strive to find ways to better serve the people of our communities, and we’re devoted to providing the kind of personal attention you just can’t find anywhere else.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

FierceBiotech | February 03, 2020

news image

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Read More

Pharmacy Market

CURE PHARMACEUTICAL RECEIVES PATENT APPROVAL FOR ITS CUREFILM BLUE™ TECHNOLOGY

CURE Pharmaceutical Holding Corp. | November 17, 2021

news image

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ’331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the pr...

Read More

Business Insights

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

news image

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More

Pharmacy Market

ASIERIS DEEPENS STRATEGIC PARTNERSHIP WITH UROVIU TO FURTHER DEVELOP INTEGRATED DIAGNOSIS AND TREATMENT PLATFORM FOR BLADDER CANCER

PRNewswire | May 19, 2023

news image

Asieris Pharmaceuticals a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation ("UroViu"). Asieris Pharmaceuticals will obtain exclusive global rights to UroViu's patented technology of portable single-use cystoscope in the field of fluorescent imaging. Under the agreement, Asieris Pharmac...

Read More
news image

GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

FierceBiotech | February 03, 2020

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Read More
news image

Pharmacy Market

CURE PHARMACEUTICAL RECEIVES PATENT APPROVAL FOR ITS CUREFILM BLUE™ TECHNOLOGY

CURE Pharmaceutical Holding Corp. | November 17, 2021

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ’331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the pr...

Read More
news image

Business Insights

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More
news image

Pharmacy Market

ASIERIS DEEPENS STRATEGIC PARTNERSHIP WITH UROVIU TO FURTHER DEVELOP INTEGRATED DIAGNOSIS AND TREATMENT PLATFORM FOR BLADDER CANCER

PRNewswire | May 19, 2023

Asieris Pharmaceuticals a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation ("UroViu"). Asieris Pharmaceuticals will obtain exclusive global rights to UroViu's patented technology of portable single-use cystoscope in the field of fluorescent imaging. Under the agreement, Asieris Pharmac...

Read More